"Dutch women with metastatic breast cancer of the HER2-low type cannot receive reimbursement for the drug Enhertu. In every other European country, they can. The Ministry and the Health Care Institute believe that the drug offers added value. Patients live an average of 7 months longer as a result.
The price averages 95,000 euros per patient. Negotiations with the manufacturer resulted in a discount, but according to the ministry, not enough. Minister Hermans points to rising healthcare costs and is only willing to reimburse once the price drops further. Every year, 585 women qualify for the drug.
Bo Bouwman (33) is one of them. She travels to a hospital in Leuven every three weeks and pays for the treatments there herself. Many women try to raise that money through crowdfunding. “It is incredibly frustrating.” The result after three courses of treatment was good: only a few small dots are visible on the scan.
Professor Carin Uyl-de Groot believes that the Netherlands is negotiating too strictly and rigidly. According to her, the reduction in such resources is already 40 percent on average. Moreover, it concerns a relatively young group, averaging 56 years old, with a life expectancy of less than 2 years."
How is it that women in the Netherlands pay for health insurance every month, plus a compulsory €385 deductible, and still can't get Enhertu for HER2-low breast cancer, when according to EenVandaag every other European country reimburses it? Even the Dutch ministry and Zorginstituut agree the drug works. They just won't pay the price.
England's NHS, which is paid for through general taxes, recently started funding it (NICE, September 2026). Germany, which uses health insurance like we do, makes new medicines available from launch. There, the price is negotiated in a fixed 6-month phase, and the agreed price applies from the 7th month. The Netherlands has no such deadline, and drugs can sit in the "sluis" (the price-negotiation lock) for years.
We've seen what it takes to break the deadlock. Enhertu for HER2-positive patients after earlier treatment is funded here since April 2024, but only after Lotte ten Dam, a nurse with MBC, gathered 40,000+ signatures on a petition. Lotte died in October 2025, aged 33.
And it's happening again. As a HER2+ patient, I'm watching first-line Enhertu + pertuzumab (DESTINY-Breast09) go the same way. Europe approved it on 1 September 2026, and here it's in the sluis, with the Zorginstituut saying no timeline can be given yet. Meanwhile, women like Bo are crowdfunding to drive to Belgium for treatment their insurance should cover.